Barbara Formisano

727 total citations
21 papers, 536 citations indexed

About

Barbara Formisano is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Barbara Formisano has authored 21 papers receiving a total of 536 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 11 papers in Epidemiology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Barbara Formisano's work include Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (7 papers) and Neuroblastoma Research and Treatments (5 papers). Barbara Formisano is often cited by papers focused on Neuroendocrine Tumor Research Advances (11 papers), Lung Cancer Research Studies (7 papers) and Neuroblastoma Research and Treatments (5 papers). Barbara Formisano collaborates with scholars based in Italy, United Kingdom and United States. Barbara Formisano's co-authors include Emilio Bajetta, Sara Pusceddu, Roberto Buzzoni, Laura Catena, Marco Platania, E. Bichisao, Giuseppe Procopio, Leonardo Ferrari, Elena Verzoni and Sara De Dosso and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Oncotarget.

In The Last Decade

Barbara Formisano

21 papers receiving 526 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Formisano Italy	12	452	297	197	104	76	21	536
W. Victoria Lai United States	11	558 1.2×	359 1.2×	93 0.5×	200 1.9×	55 0.7×	24	669
Amanda Beras United States	3	511 1.1×	271 0.9×	77 0.4×	146 1.4×	44 0.6×	7	580
Dorian R.A. Swarts Netherlands	8	390 0.9×	402 1.4×	244 1.2×	68 0.7×	6 0.1×	11	473
Luka Ozretić Germany	8	344 0.8×	226 0.8×	52 0.3×	215 2.1×	24 0.3×	13	516
Atsuko Umezawa Japan	8	181 0.4×	126 0.4×	63 0.3×	97 0.9×	15 0.2×	12	320
PE Postmus Netherlands	10	329 0.7×	218 0.7×	75 0.4×	198 1.9×	6 0.1×	16	435
Hilliard F. Seigler United States	6	273 0.6×	136 0.5×	62 0.3×	83 0.8×	45 0.6×	7	302
Sivuonthanh Lam United States	5	619 1.4×	412 1.4×	19 0.1×	173 1.7×	54 0.7×	11	662
Lida Bubuteishvili‐Pacaud United States	8	316 0.7×	189 0.6×	147 0.7×	84 0.8×	32 0.4×	21	357
Lynnette Fernandez‐Cuesta France	13	501 1.1×	341 1.1×	139 0.7×	160 1.5×	4 0.1×	29	699

Countries citing papers authored by Barbara Formisano

Since Specialization

Citations

This map shows the geographic impact of Barbara Formisano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Formisano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Formisano more than expected).

Fields of papers citing papers by Barbara Formisano

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Formisano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Formisano. The network helps show where Barbara Formisano may publish in the future.

Co-authorship network of co-authors of Barbara Formisano

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Formisano. A scholar is included among the top collaborators of Barbara Formisano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Formisano. Barbara Formisano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Provenzano, Leonardo, Riccardo Lobefaro, Francesca Ligorio, et al.. (2023). The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis. Therapeutic Advances in Medical Oncology. 15. 2610714–2610714. 17 indexed citations

Pusceddu, Sara, Roberto Buzzoni, Claudio Vernieri, et al.. (2016). Metformin with Everolimus and Octreotide in Pancreatic Neuroendocrine Tumor Patients with Diabetes. Future Oncology. 12(10). 1251–1260. 34 indexed citations

Pusceddu, Sara, Filippo de Braud, Giuseppe Lo Russo, et al.. (2016). How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. Oncotarget. 7(28). 44841–44847. 13 indexed citations

Pusceddu, Sara, et al.. (2015). Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.. PubMed. 100(6). e286–9. 18 indexed citations

Pusceddu, Sara, Filippo de Braud, Alice Lorenzoni, et al.. (2015). Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology. 11(13). 1947–1959. 6 indexed citations

Pusceddu, Sara, Roberto Buzzoni, Luca Giacomelli, et al.. (2014). The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrine tumor receiving everolimus plus somatostatin analog treatment.. Journal of Clinical Oncology. 32(15_suppl). e15172–e15172. 1 indexed citations

Bajetta, Emilio, Filippo Pietrantonio, Roberto Buzzoni, et al.. (2013). Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer. American Journal of Clinical Oncology. 37(6). 545–549. 11 indexed citations

Pietrantonio, Filippo, Pamela Biondani, Filippo de Braud, et al.. (2012). Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen. Translational Oncology. 5(3). 155–159. 17 indexed citations

Pusceddu, Sara, Emilio Bajetta, Maria Luisa Carcangiu, et al.. (2011). A literature overview of primary cervical malignant melanoma: An exceedingly rare cancer. Critical Reviews in Oncology/Hematology. 81(2). 185–195. 60 indexed citations

10.

Platania, Marco, Francesco Agustoni, Barbara Formisano, et al.. (2011). Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Targeted Oncology. 6(3). 181–186. 7 indexed citations

11.

Catena, Laura, E. Bichisao, Massimo Milione, et al.. (2011). Neuroendocrine tumors of unknown primary site: Gold dust or misdiagnosed neoplasms?. Tumori Journal. 97(5). 564–567. 26 indexed citations

12.

Valente, Monica, Laura Catena, Massimo Milione, et al.. (2010). Common Diagnostic Challenges in the Histopathologic Diagnosis of Neuroendocrine Lung Tumors: A Case Report. Case Reports in Oncology. 3(2). 202–207. 6 indexed citations

13.

Pusceddu, Sara, Laura Catena, Monica Valente, et al.. (2010). Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis.. PubMed. 2(1). 16–20. 13 indexed citations

14.

Catena, Laura, A. Carbone, Massimo Milione, et al.. (2009). 1323 mTOR expression in gastrointestinal (GI) tract poorly differentiated endocrine carcinoma (PDEC). European Journal of Cancer Supplements. 7(2). 145–146. 1 indexed citations

15.

Bajetta, Emilio, Laura Catena, Monika Ducceschi, et al.. (2009). Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes. Tumori Journal. 95(4). 501–507. 4 indexed citations

16.

Bajetta, E., Michele Del Vecchio, Alberto Fusi, et al.. (2006). Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma. Annals of Oncology. 17(4). 571–577. 83 indexed citations

17.

Bidoli, Paolo, Nicoletta Zilembo, Diego Cortinovis, et al.. (2006). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Annals of Oncology. 18(3). 461–467. 28 indexed citations

18.

Bajetta, Emilio, Laura Catena, Giuseppe Procopio, et al.. (2006). Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. Cancer Chemotherapy and Pharmacology. 59(5). 637–642. 171 indexed citations

19.

Bidoli, Paolo, Diego Cortinovis, L. Isa, et al.. (2005). Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology. 23(16_suppl). 7118–7118. 4 indexed citations

20.

Bajetta, Emilio, Simonetta Chiara Stani, Nadia Zaffaroni, et al.. (2003). Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IVnon-small-cell lung cancer. Annals of Oncology. 14(2). 242–247. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact